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Abstract
Background: To improve access to treatment in the private retail sector a new class of outlets known as
accredited drug dispensing outlets (ADDO) was created in Tanzania. Tanzania changed its first-line treatment for
malaria from sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (ALu) in 2007. Subsidized ALu was made
available in both health facilities and ADDOs. The effect of these interventions on access to malaria treatment was
studied in rural Tanzania.
Methods: The study was carried out in the villages of Kilombero and Ulanga Demographic Surveillance System
(DSS) and in Ifakara town. Data collection consisted of: 1) yearly censuses of shops selling drugs; 2) collection of
monthly data on availability of anti-malarials in public health facilities; and 3) retail audits to measure anti-malarial
sales volumes in all public, mission and private outlets. The data were complemented with DSS population data.
Results: Between 2004 and 2008 access to malaria treatment greatly improved and the number of anti-malarial
treatment doses dispensed increased by 78%. Particular improvements were observed in the availability (from 0.24
shops per 1,000 people in 2004 to 0.39 in 2008) and accessibility (from 71% of households within 5 km of a shop
in 2004 to 87% in 2008) of drug shops. Despite no improvements in affordability this resulted in an increase of the
market share from 49% of anti-malarial sales 2005 to 59% in 2008. The change of treatment policy from SP to ALu
led to severe stock-outs of SP in health facilities in the months leading up to the introduction of ALu (only 40%
months in stock), but these were compensated by the wide availability of SP in shops. After the introduction of
ALu stock levels of the drug were relatively high in public health facilities (over 80% months in stock), but the drug
could only be found in 30% of drug shops and in no general shops. This resulted in a low overall utilization of the
drug (19% of all anti-malarial sales)
Conclusions: The public health and private retail sector are important complementary sources of treatment in
rural Tanzania. Ensuring the availability of ALu in the private retail sector is important for its successful uptake.
Background
It is increasingly recognized that the Roll Back Malaria
(RBM) Partnership target of ‘80% of malaria patients
receiving effective treatment within 24 hours’ cannot be
achieved in sub-Saharan Africa unless anti-malarial
drugs are made available outside the formal health
sector [1-3]. The public health sector plays a central
role in the delivery of key curative and preventative
interventions for malaria in most African countries.
However, health facilities alone do not guarantee satis-
factory levels of access in countries where malaria is
endemic. Surveys conducted between 2007 and 2008 in
11 African countries found that despite large increases
in the number of anti-malarial treatments supplied
through the public health sector, only 15% of children
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therapy (ACT) [4].
As a result, it has been argued that the delivery of
anti-malarials needs to be supplemented by additional
distribution mechanisms. This can be achieved through:
1) community case management and 2) strengthening
the role of the private retail sector. The World Health
Organization (WHO) is increasingly promoting the pro-
vision of anti-malarial drugs through community health
workers with its Home Management of Malaria (HMM)
strategy [5]. However, the WHO also recognizes the
importance of private retailers [6] and various interven-
tions aimed at improving their services have been devel-
oped and piloted in different country settings [7].
Reviews of the available literature reveal that shops
are often preferred to health facilities as a first treat-
ment action [8,9]. Retailers tend to be more accessible,
have longer and more flexible opening hours, are will-
ing to negotiate charges and offer credit, are more
polite and friendlier and are generally perceived as
being cheaper. Patients also seek treatment in the pri-
vate sector out of necessity since public health facilities
experience frequent stock-outs. However, the private
retail sector is often poorly regulated in low and mid-
dle income countries. Common opportunistic practices
include illegal stocking of prescription-only medicines,
the use of unqualified staff and referral by health facil-
ity staff to private outlets in which they have a finan-
cial stake [10-12]. The advent of ACT compounds the
problem further. In absence of regulation, people are
likely to buy cheaper and less effective drugs from the
private retail sector. Furthermore the misuse of ACT
and the use of artemisinin monotherapies could contri-
bute to the emergence and spread of artemisinin
resistance.
In the past five years, two major interventions which
directly affect access to malaria treatment have been
implemented in Tanzania. Firstly, in 2002 the Tanza-
nian Food and Drug Administration (TFDA) registered
a new class of drug shops known as accredited drug
dispensing outlets (ADDOs). With over 8,000 outlets
nation wide, drug shops are an important source of
anti-malarial treatment in Tanzania, but unqualified
staff invariably sells drugs they are not legally author-
ized to stock [13-15]. The aim of ADDOs is to address
this poor state of regulation by upgrading existing drug
shops (known as Part II) to properly operated outlets
through a combination of dispenser training, financial
incentives, accreditation and regulation [16]. Motivated
by the experience of pilots conducted in the Ruvuma
Region with support from the Bill and Melinda Gates
Foundation (BMGF), the Ministry of Health and TFDA
have planned the conversion of all Part II drug shops in
the country by 2010 [17].
Secondly, in 2006 SP was abandoned in favour of arte-
mether-lumefantrine (ALu, trade name Coartem®,
Novartis AG) as first-line treatment for malaria due to
high levels of resistance to SP. The actual introduction
of ALu in health facilities was delayed until January
2007. ALu is currently unaffordable for most of the
population because of the high market price of USD
8-10 for an adult dose. Thanks to support from the Glo-
bal Fund to Fight AIDS, TB and Malaria (GFATM) the
drug is provided free to all government health care facil-
ities, where it should be made available free to children
under the age of five and pregnant women; and at subsi-
dized price of TSH 300 (USD 0.25) to other patients.
Subsidized ALu was also made available in all ADDOs
in the country by the end of 2007. Initial plans to
upscale this scheme are likely to be superseded in 2010
by the Affordable Medicines Facility for malaria
( A M F m ) .T h eA M F ma i m st om a k eA C Ta v a i l a b l ea t
the cost of the previous generation of anti-malarials by
negotiating with the manufacturers to reduce the price
of their ACT and subsidizing them heavily for purchase
by specified national importers. It is expected that drugs
will be available at about USD 0.20-0.50 to patients.
Tanzania and Zanzibar are among the 10 countries
invited to pilot a first phase of this subsidy as from mid
2010 [18].
This study presents a unique set of longitudinal data
on availability, accessibility, costs and uptake of anti-
malarial treatment in both the private retail and public
health sectors. The data were collected between 2004
and 2008 in two districts of the Morogoro Region in the
frame of the ACCESS programme, which aims at
improving and understanding access to malaria treat-
ment [19]. The results presented here are complemen-
ted by treatment-seeking surveys which evaluated
changes in treatment outcomes (i.e. the user perspec-
tive) [20]. This experience is of great relevance to other
settings, as ACT is being adopted throughout most of
Africa as first-line treatment for malaria and ACT subsi-
dies will be introduced widely in the private sector
through the AMFm.
Methods
Study setting
The study was carried out between 2004 and 2008 in the
rural villages of the Kilombero and Ulanga Demographic
and Surveillance System (DSS) and in the semi-urban set-
ting of Ifakara town in south-central Tanzania (Figure 1).
The rural DSS area covers 25 villages (13 in the Kilo-
mbero District and 12 in Ulanga District). The popula-
tion in mid-2004 was 73,977 and increased at an average
rate of 5% per year, resulting in a population of just over
92 203 in mid-2008. The population of Ifakara town was
45,518 in 2002 according to the last national census [21].
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nial with differences between the rural and semi-urban
settings. Overall transmission has been declining over
the past 10 years. A study conducted in the area
between 2001 and 2003 reported an entomological
inoculation rate (EIR) of 349 infective bites per person
per year (ib/p/y) [22], but according to recent data it
has declined to 81 ib/p/y (Russell et al., unpublished
data). EIR data for Ifakara town suggest that the trans-
mission rate is about a log order smaller than in the
surrounding rural areas [23]. Treatment-seeking surveys
carried out in 2004, 2006 and 2008 within the frame of
the ACCESS programme found on average twice as
many fever cases in the rural areas compared to Ifakara
town (Alba et al., unpublished data).
There are six health facilities (three public dispen-
saries, one public health centre and two faith-based dis-
pensaries) in the Kilombero rural DSS area and eight
health facilities (five public dispensaries, one health cen-
tre and two faith-based dispensaries) in the Ulanga rural
DSS area. The Designated District Hospital in Ifakara
serves as a referral point for all the facilities in the study
area. There is only one Part I pharmacy in the study
area, which is located in Ifakara town. The area has
been described in more detail elsewhere [19,24].
Data collection activities are summarized in Table 1
and described in detail below. The routine monitoring in
health facilities and the shop censuses, combined with
DSS data, provided information on availability and acces-
sibility of sources of anti-malarial drugs. The retail audits
provided data on prices and uptake of anti-malarial
drugs.
Routine monitoring in health facilities
Every other month a team of trained field workers vis-
ited the ten public health facilities in the rural DSS area
(four in Kilombero and six in Ulanga) to collect end-of-
month anti-malarial drug stock data from the Health
Management and Information System (HMIS) ledger
books, using validated data collection tools. Data could
not be collected from the faith based facilities as they
are not legally required to record drug stock in ledger
books, rendering systematic collection of the data diffi-
cult. In 2004 the GPS locations of all the health facilities
i nt h ea r e aw e r er e c o r d e dw i t hah a n d - h e l dG P Su n i t
(Garmin® e-Trex, Garmin® Ltd).
The percentage of facility-months in stock of a given
anti-malarial over the year was calculated as an indicator
of drug availability. First, an average estimate of yearly
drug availability was calculated for each drug and each
health facility. Unfortunately, the data on drug availabil-
ity were missing in the ledger books for many months.
Anecdotal evidence suggests that facility staff tended not
to fill in the entry on end-of-month stocks when the
Figure 1 Map of Kilombero and Ulanga Districts showing Ifakara Town and the Demographic Surveillance System (DSS). Source: [24].
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of any other information, months with missing data
were considered as “out of stock”. If a health facility had
more than 25% missing values it was excluded from the
average to avoid skewing estimates of yearly drug avail-
ability towards unrealistically low values. Then an aver-
age estimate of anti-malarial availability for the area was
calculated by averaging the yearly estimates from all the
health facilities. The estimate was deemed inconclusive
if more than 25% facilities had to be excluded from the
average estimate.
The health facility data were complemented with
population numbers and household locations to provide
standardized indicators of availability and accessibility of
health facilities. Population counts down to village level
were available for every year between 2004 and 2008
from the DSS database. GPS positions were available
from the DSS database for 85% (16141/18840) of house-
holds in 2004 and 90% (18580/20579) of households in
2008. An indicator of availability of health facilities was
constructed as the number of shops per 1,000 popula-
tion, and an indicator of accessibility as the average dis-
tance between households and the nearest health facility.
Shop census
Repeated cross sectional shop censuses were carried out
every year in the rural DSS area and in Ifakara town. All
shops potentially selling drugs (general stores, kiosks,
Part II drug stores and ADDOs) were visited by a team
of nine trained field workers who recorded the outlet’s
stock and location using tools and methodology devel-
oped and previously applied in the area [3,25]. The only
Part I pharmacy was not visited. The primary aim of the
census was to assess the type and brand of drugs avail-
able in each type of outlet. The analysis of the baseline
study in 2004 was published by Hetzel et al.[ 2 5 ]a n d
the results presented here provide a longitudinal assess-
ment of the changes between 2004 and 2008. The sec-
ondary aim of the census was to assess shopkeepers’
knowledge about signs, symptoms and treatment of
malaria. Results will be presented elsewhere (Dillip
et al., in preparation).
Data were collected using a structured questionnaire
and the location of each shop was recorded with a
hand-held GPS unit. The field work was overseen by the
same supervisor in all years. The supervisor visited all
the village and hamlet leaders prior to the censuses to
inform them and to answer any queries. Every year, field
interviewers were provided with an inventory of all the
outlets identified in the previous year’s census and were
instructed to visit every outlet on the list, as well as any
new outlet they encountered. Random quality checks
were performed by a research scientist who visited the
field sites shortly after the field workers.
Estimates of availability and accessibility of shops
stocking drugs were constructed using the methodology
outlined for health facilities. Population counts were
estimated for Ifakara town by adjusting the 2002 census
count with the annual growth rate in the rural DSS area.
Retail audits
Two retail audits of anti-malarial drugs were conducted
in the rural DSS during the shop censuses of 2005 and
2008. The methodology developed by Goodman et al
[26,27] was applied. The retail audit included all outlets
selling or dispensing drugs, i.e. all health facilities (pub-
lic and faith-based) and drug shops (Part II drug shops
and ADDOs), as well as the few general shops found to
stock anti-malarial drugs during the shop census. The
aim of the study was to estimate total anti-malarial sales
Table 1 Summary of data collection activities
Activity Collection period
(month.year)
Sample Location
Routine monitoring in health facilities
1) Collection of monthly data on availability of anti-malarial drugs
in all public health facilities from ledger books
1.2005 - 12.2008 10 Rural villages (DSS)
2) GPS location of each health facility
Shop census
Census of all shops potentially selling drugs providing quantitative data on 5.2004 - 7.2004 758 Rural villages (DSS) and Ifakara Town
3.2005 - 7.2005 790
1) Availability of shops selling anti-malarial drugs 4.2006 - 7.2006 878
2) Availability of anti-malarial drugs 4.2007 - 8.2007 1074
3) GPS location of each shop 4.2008 - 9.2008 1082
Retail audits
1) Measurement of anti-malarial sales during a two-week period
in all outlets (shops and health facilities)
4.2005 - 7.2005 78 Rural villages (DSS)
2) Retail prices of each anti-malarial drug 4.2008 - 7.2008 66
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sales of each anti-malarial drug across each type of
outlet.
The retail audit data were collected over two consecutive
visits two weeks apart. On the first visit, which coincided
with the shop census visit, field interviewers recorded
stock levels for each anti-malarial drug. On the second
visit they recorded stock levels and any deliveries since
their last visit, as well as any drugs that had been given out
for any other reason e.g. thrown away or returned to
wholesalers. Two weeks was considered a reasonable recall
period for wholesale deliveries. The exact number of
tablets, bottles or vials was counted where possible. When
tablets were kept in tins the following information was col-
lected in order to estimate the number of tablets present:
the height of the tablets in the tin when full, the height of
tablets on the day of visit and the number of tablets in a
full tin. In addition the reported retail price per single unit
(be it a tablet, bottle or vial) was recorded. The retail audit
was carried out once a year (in approximately the same
months) as no significant seasonal differences were found
in the previous study in which two surveys per year were
conducted [27].
Daily sales were calculated or estimated for each anti-
malarial. Sales between the two visits were calculated as:
Sales = (total at first visit) + (deliveries between first
and second visit) - (stocks thrown away or transferred
to other shops/facilities) - (total at second visit). The
number of tablets, bottles of syrup and vials was con-
verted into the equivalent number of adult doses in
order to calculate the total anti-malarial sales of differ-
ent types of anti-malarials. Daily sales were calculated
by scaling down up or down pro rata according to the
number of days between the two audit visits. If total
sales volumes could not be calculated (because drug
levels were not recorded on the first or the second
visit), they were estimated by a multiple imputation.
With this statistical technique missing values are
imputed several times based on random draws from the
conditional distribution of the missing observations
given the observed data and covariates (drug levels on
the first or second visit, type of outlet, type of drug and
drug formulation). In this case three draws were consid-
ered enough and the average between the three imputa-
tions kept for analysis. Multiple imputation was deemed
appropriate as there were no indications that the data
were not missing at random.
Reported drug prices were adjusted for inflation to
reflect actual changes in purchasing power. The 2005
drug prices were inflated to real 2008 values on the
basis of consumer price indices [28]. An inflation factor
of 1.25 was derived from the mean yearly inflation
values published by the Tanzania National Bureau of
Statistics (NBS) [29].
Data entry and analysis
Data were double entered using Microsoft FoxPro and
Microsoft Access (Microsoft Corp. Seattle, USA) and
checked for coding errors and consistency. Intercooled
Stata 10 (Stata Corp., College Station, TX, USA) was
used for data management and analysis. Logistic and
Poisson regressions provided odds ratios (OR) and inci-
dence rate ratios (IRR) to estimate changes over time or
differences between areas. ORs and IRRs indicate an
average increase per year between the years of observa-
tion ("year” is entered in the regression as a linear vari-
able) unless it is explicitly stated that the increase is not
linear and is from a given year to another ("year” is
entered as a categorical variable). Differences in medians
between years were tested using a two-sample Wilcoxon
rank-sum (Mann-Whitney) test. Distances were calcu-
lated with ArcMap Version 9.1 (ESRI Inc.)
Ethics
The National Institute for Medical Research of the Uni-
ted Republic of Tanzania (NIMR/HQ/R.8a/Vol.IX/236,
16
th September 2003) granted ethical clearance for the
study Shop keepers and health facility staff gave
informed consent to participating in the study and were
given feedback of the study results.
Results
Availability and accessibility of anti-malarials in public
health facilities
Drug availability data were collected for ten facilities
over four years for four drugs (two years for ALu) i.e.
1,680 facility-months but only 1,380 facility-months of
observation could be included in the analysis. As a
result out of the 14 yearly overall availability estimates
were deemed inconclusive (Figure 2).
Towards the end of 2006, just before the introduction
of to ALu, health facilities experienced severe stock-outs
of SP. On average throughout the year the drug was
only available 40% (38/96) of the months with three
facilities reporting stockouts for more than 10 months.
This was mainly due a delay in the introduction of ALu
without additional SP orders to compensate. The avail-
ability of quinine and amodiaquine was much higher as
the drugs were reported to be available 66% (78/120)
and 58% (70/120) of the time, respectively (Figure 2).
However, four facilities were out of stock of all three
anti-malarials for a mean of 2.8 (sd = 1) months of the
year. Since the introduction of ALu availability of anti-
malarial drugs has greatly improved. In 2007 and 2008
ALu was available for more than 80% of the months of
the year (90/108 in 2007 and 88/108 in 2008).
The availability and accessibility of health facilities was
only slightly affected by population growth. The avail-
ability of public health facilities decreased slightly but
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1,000 people (10/73,977) and in 2008 this figure
declined to 0.11 (10/92,203) (IRR = 0.81 p = 0.712 from
2004 to 2008). The median distance from a household
to a facility marginally increased from 2.25 km (IQR =
4.31) to 2.37 km (IQR = 4.75) (z = -5.388 p < 0.001)
and the proportion of households located within 5 km
of a health facility decreased from 73% (11,858/16,141)
to 70% (12,990/18,580) in 2008 (OR = 0.90 p < 0.001
from 2004 to 2008).
Availability and accessibility of malaria treatment in drug
shops
The number of shops included in the census increased
on a yearly basis (Table 2). Every year general shops
(permanent structures and kiosks) consistently
accounted for 95% of all shops potentially selling drugs,
while the rest were Part II drug shops and ADDOs. The
number of Part II drug shops decreased considerably
after 2006 as they were progressively upgraded to
ADDOs. Overall the number of drug shops (Part II
drugs stores and ADDOs) increased from 34 to 59
between 2004 and 2008.
Across all years a high proportion of general shops
s t o c k e ds o m et y p eo fd r u ga n dah i g hp r o p o r t i o no f
drug shops stocked anti-malarials, but a varying and
much smaller proportion of general shops stocked anti-
malarials (Figure 3). Between 2004 and 2008 an average
of 68% of general shops stocked drugs (mainly
antipyretics), with no significant differences between dis-
tricts or between the rural areas and Ifakara town. How-
ever, few of these were found to sell anti-malarial drugs.
The proportion of general shops selling anti-malarials
never exceeded a peak of 9% (18/199 in Ulanga and 23/
293 in Kilombero) in 2005 in the rural DSS villages and
3% (5/185) in Ifakara in 2004 and decreased consider-
ably thereafter to 3% (5/501 in Ulanga and 10/442 in
Kilombero) in the rural DSS and to 0% (0/380) in Ifa-
kara town in 2008 (DSS IRR = 0.87 p = 0.018, Ifakara
IRR = 0.64 p = 0.013 between 2004 and 2008). The pro-
portion of drug shops (Part II and ADDOs) storing anti-
malarial drugs was 86% (31/36) in 2004, 100% (42/42) in
2005, 84% (37/44) in 2006 and over 98% in 2007 (54/55)
and 2008 (58/59).
There is evidence of greater availability of drug shops,
even accounting for population growth. While the abso-
lute number of anti-malarial retail points (drug shops
and general shops) increased over the study period from
58 in 2004 to 74 in 2008, the number of shops per
1,000 people did not change significantly over the years
and fluctuated around 0.73 shops per 1,000 people in
rural DSS areas and 0.34 in Ifakara town (Figure 4). In
contrast, the availability of drug shops alone did increase
over the years, although not linearly, from 0.23 (29/
123260) shops per 1,000 people in 2004 to 0.39 (59/
151,260) in 2008 (IRR = 1.72 from 2004 to 2008 p =
0.019). Average rates mask differences at district and
village level. The Kilombero rural DSS generally had
Figure 2 Availability of anti-malarial drugs in public health facilities in the rural DSS area. Note ALu was introduced in January 2007.
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(IRR = 0.71 p = 0.005) and drug shops (IRR = 0.53, p =
0.001) compared to the Ulanga rural DSS. Moreover,
half of the 14/25 villages which did not have drug shops
in 2004 still did not have any in 2008. Three of these
did not have any health facilities either, and this
accounts for 6% (5442/92203) of the total rural DSS
population.
Amodiaquine and SP were the most commonly avail-
able anti-malarials in both general shops and drug shops
(Figure 5). In drug shops, the anti-malarial most com-
monly available was SP (90% of shops i.e. 210/234 over
the study period), closely followed by amodiaquine (86%
i.e. 200/234) and quinine (80% i.e. 187/234). ALu was
available in 2% (1/43) of the drugs stores in 2006
(unsubsidized), 7% (4/54) in 2007 and 29% (17/58) in
2008. Interestingly, chloroquine could still be found in
2004 and in 2005 in one drug shop in a remote village
of the Kilombero rural DSS area. Figure 5 gives a break
down by year of these figures.
Table 2 Number of shops censused, by type
2004 2005 2006 2007 2008
General shops (including kiosks) Kilombero DSS 343 293 313 385 442
Ulanga DSS 201 199 180 213 201
Ifakara town 185 256 341 421 380
Total 729 748 834 1019 1023
Part II drug stores Kilombero DSS 16 22 17 8 6
Ulanga DSS 3 9 4 2 3
Ifakara town 10 11 17 1 1
Total 29 42 40 11 10
ADDOs Kilombero DSS 0 0 0 18 22
Ulanga DSS 0 0 4 8 7
Ifakara town 0 0 0 17 20
Total 0 0 4 43 49
Total Kilombero DSS 359 315 330 412 470
Ulanga DSS 204 208 190 223 211
Ifakara town 195 267 358 439 400
Total 758 790 878 1074 1083
Figure 3 Proportion of general stores selling any drugs and anti-malarials. Note: vertical axis differs between two graphs.
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in the drug shops of Ifakara, ALu was also available in
the rural areas. The proportion of shops storing artemi-
sinin monotherapies grew until 2007, when up to 11 out
of 55 (20%) shops stored drugs containing either artesu-
nate, artemether or dihydroartemisinin (Figure 5). In
2008, this proportion decreased to 12% (7/59), probably
as a result of tighter national and international regula-
tions on the distribution of artemisinin monotherapies.
However, it is worth noting that these artemisinin deri-
vatives could be found in Ifakara but hardly reached the
more rural villages, most likely because of their very
high prices. ALu tended to be more available in Ifakara
than in rural areas (Ifakara 8/13 i.e. 38.1% of drug shops
Figure 4 Availability of retail outlets selling drugs, per 1000 population.
Figure 5 Availability of different anti-malarial drugs in private retail outlets. Note: vertical axis differs between two graphs.
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2/10 i.e. 20%).
D r u gs h o p sb e c a m em o r ea c c e s s i b l ea f t e rt h ei n t r o -
duction of ADDOs. Across all years drug shops were
more likely to be found in the most populous areas, but
different patterns were noted for ADDOs and drug
shops. Both in 2004 and in 2008 a significant association
was found between the presence of any drug shop in a
village and the size of the village (2004 OR = 2.6 for
every 1,000 increase in population p = 0.016, 2008 OR =
2.6 p = 0.048). However, in 2008 the association
b e t w e e nt h ep r e s e n c eo fa nA D D Oi nav i l l a g ea n dt h e
size of the village was much smaller (OR = 1.7 p =
0.077) suggesting that ADDOs were also opened purpo-
sefully in less populous areas. This resulted in an
increase in the number of households located within
5 km from a drug shop from 71.5% (3,848/16,141) to
87% (11,662/18,580) (OR = 5.38 p < 0.0001 from 2004
to 2008) (Figure 6). The median distance from a drug
shop to a household nearly halved during the study per-
iod, decreasing from 2.2 km (IQR = 4.8) to 1.2 km (2.6)
(z = 32.234 p < 0.0001).
Sales of anti-malarial drugs in shops and health facilities
In 2005 a total of 366 anti-malarial products were fol-
lowed from 77 retail outlets (31 drug stores, 37 general
stores, five kiosks and 14 health facilities). In 2008 a
total of 409 products were followed from 66 outlets (10
drug stores, 12 general stores, three kiosks, 27 ADDOs
and 14 health facilities). Sales levels could not be calcu-
lated and were estimated for 6% (44/775) items because
drug levels were not recorded either in the first or in
the second visit (see methods).
The analysis of daily sales revealed a near doubling
in the number of anti-malarial doses dispensed
between 2005 and 2008 and the increasing importance
of drug shops as a source of anti-malarials. An esti-
mated 315 equivalent adult anti-malarial doses were
dispensed per day from all facilities and shops in the
rural DSS areas in 2005 while 560 doses were dis-
pensed in 2008 (78% increase). The proportion of anti-
malarial drugs sold in drug shops increased from 49%
(153.5/315.3) in 2005 to 59% (330.2/560.3) in 2008
(OR = 1.51 p = 0.036) (Table 3 and Figure 7). The
increase in the use of drug shops was not at the
expense of public health facilities, but at the expense
of general shops and faith based facilities. Indeed, the
proportion of doses sold in general shops and faith
based health facilities decreased but there was no sig-
nificant difference in terms of anti-malarials dispensed
in health facilities (79.4/315.3 i.e. 25% in 2005 vs.
169.9/560.3 i.e. 30% in 2008 OR = 1.29 p = 0.115)
The sales of SP remained very high in 2008 despite
the change of treatment policy to ALu. In 2005 64% of
all anti-malarial sales consisted of SP and in 2008 it still
accounted for 51% of all anti-malarial sales. ALu only
accounted for 19% of total sales in 2008, 68% (71.1/
104.0) of which were in public health facilities, 14%
Figure 6 Cumulative percentage of households within a given distance to the nearest drug shop.
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Page 9 of 15(14.8/104.0) from faith based health facilities and 17%
(18.1/104.0) from drug shops.
Prices were generally higher in drug shops where they
also increased considerably over time. Prices of anti-
malarials were compared between 2005 and 2008 in
drug shops and public health facilities only (Table 4)
although six out of 10 health facilities did not provide
any pricing information. In 2005 health facilities
reported selling SP adult doses at an average of USD
0.25 (USD 0.32 in 2008 prices) whereas it was sold for
U S D0 . 3 7( U S D0 . 4 5i n2 0 0 8p r i c e s )o na v e r a g ei nd r u g
shops. In 2008 two of the facilities which provided
prices reported dispensing ALu packs for children under
the age of eight free, whereas two reported selling them
for USD 0.25. Adult ALu and SP doses were reported to
be sold for USD 0.25 in health facilities. Both SP and
ALu were much more expensive in shops where sellers
reported selling an ALu dose for USD 1.27 and SP
doses for USD 0.67. Adjusting for inflation these price
differences translate into a 20% decrease in the price of
Table 3 Number of equivalent adult doses sold per day in all shops and health facilities (HF) in the DSS rural areas
and share out of total in the type of outlet
2005 2008
Public
HF
Faith
Based
HF
Drugs
shops
General
shops
Total Public
HF
Faith Based
HF
Drugs
shops
General
shops
Total
Amodiaquine 22.4
(28.2%)
21.0
(42.4%)
43.4
(28.3%)
10.8
(32.8%)
97.6
(30.9%)
64.7
(38.1%)
9.6
(29.2%)
62.1
(18.8%)
4.3
(21.2%)
140.7
(25.1%)
Chloroquine 0.9
(0.6%)
0.9
(0.3%)
-
SP 54.9
(69.2%)
26.8
(54.2%)
97.9
(63.8%)
21.9
(66.6%)
201.5
(63.9%)
26.6
(15.7%)
7.9
(24.0%)
233.6
(70.7%)
15
(78.8%)
284.1
(50.7%)
Quinine 2.1
(2.6%)
1.7
(3.4%)
11.3
(7.3%)
0.2
(0.6%)
15.3
(4.9%)
7.5
(4.4%)
7.5
(22.8%)
16.1
(4.9%)
> 0.1
(> 0.1%)
31.1
(5.1%)
ALu - - - - - 71.1
(41.8%)
14.8
(50%)
18.1
(5.5%)
104.0
(18.6%)
Artemisinin
monotherapy
- - - - - 0.1
(> 0.1%)
0.3
(> 0.1%)
0.3
(> 0.1%)
Total 79.4 49.5 153.5 32.9 315.3 169.9 32.9 330.2 20.3 560.3
Figure 7 Share of total anti-malarial sales through each outlet type.
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Page 10 of 15the first-line treatment in public health facilities. In drug
shops prices increased by 51% when comparing the
price of SP in 2005 and in 2008 and by 84% when com-
paring the price of SP in 2005 and the price of ALu in
2008.
Discussion
The findings presented here provide an independent
assessment of the changes in access to anti-malarial
treatment in the private and the public sector after the
roll-out of ADDOs and the introduction of ACT in the
Kilombero and Ulanga Districts of Tanzania. A frame-
work recently published by Obrist et al.v i e w sa c c e s sa s
the degree of fit between providers’ services and users’
means along the five dimensions of availability, accessi-
bility, affordability, adequacy and acceptability [30].
Appropriate levels of access lead to utilization of treat-
ment and eventually to improved health, provided the
treatment is of high quality. This study has concentrated
on the provider side of access and changes in levels of
availability, accessibility and affordability of treatment in
both the private health sector and the commercial retail
sector are summarized in Table 5 and Table 6. These
access indicators can be viewed as outputs in the stan-
dard evaluation terminology [31], whereas the treat-
ment-seeking surveys conducted alongside this study
focused on treatment outcomes [20]).
Overall there has been a great improvement in access
to malaria treatment. The number of anti-malarial
doses dispensed nearly doubled over the three years of
observation. Major gains were made in the private
retail sector in terms of availability and accessibility of
treatment, but availability of drugs also improved in
health facilities following the introduction of ALu. The
treatment-seeking surveys [20] conducted in the study
area found that this was accompanied by an increase
in the promptness of treatment. The data show that
the proportion of anti-malarial doses taken within
24 hours of symptom onset increased from form 80%
in 2004 to 93-97%.
Table 4 Reported retail price in Tanzanian Shillings (TSH) in drug shops and public Health Facilities (HF) of a single
adult anti-malarial dose - unless otherwise specified (USD 1 = TSH 1180 in 2008 and USD 1 = TSH 1130 in 2005)
2005 2008
Drugs shops Public HF Drug Shops Public HF
N Median
(IQR)
N Median
(IQR)
N Median
(IQR)
N Median
(IQR)
Amodiaquine
Tablets 35 0.35
(0.35 to 0.94)
4 0.35
(0.32 to 0.44)
31 0.42
(0.42 to 0.67)
-
syrup
1 36 0.72
(0.62 to 0.83)
1 0.25
(0.25 to 0.25)
38 0.99
(0.78 to 0.99)
-
Chloroquine tablets 1 0.26
(0.26 to 0.26)
---
SP 100 0.37
(0.26 to 0.79)
5 0.26
(0.26 to 0.26)
103 0.67
(0.25 to 1.27)
4 0.25
(0.13 to 0.25)
Quinine
Tablets 26 1.85
(1.85 to 1.85)
3 1.85
(1.85 to 1.85)
28 3.56
(3.56 to 3.56)
3 2.85
(1.78 to 3.56)
syrup
1 15 3.35
(2.79 to 4.18)
- 38 5.34
(5.34 to 5.34)
Injection
2 18 9.29
(7.43 to 9.29)
5 7.43
(5.58 to 9.28)
30 8.90 (8.90 to 0.68) 2 8.89 (8.89 to 8.89)
Artemether-Lumefantrine
3 m - 3 y - - 8 0.42
(0.42 to 1.06)
4 0.05
(0 to 0.18)
3 - 8 y - - 9 0.42
(0.42 to 0.84)
3 0.25
(0 to 0.25)
8 - 12 y - - 8 1.27
(1.14 to 6.99)
4 0.13
(0 to 0.13)
12 y + - - 7 1.27
(1.27 to 1.69)
4 0.25
(0.13 to 0.25)
Artemisinin monotherapies - - 2 4.68
(4.29 to 5.08)
1 dose for a child between 1 and 3 years of age
2 calculated assuming a full course of quinine is taken intra-muscularly for 7days
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Page 11 of 15There was a stark improvement in the availability of
the first-line treatment in public health facilities over
the study period. In 2008 health facilities were in stock
of ALu in over 80% of the months of the year compared
to 40% in stock of SP in 2006. It is worth noting that
the value of 80% ALu stock was determined using a
very conservative method of estimation whereby missing
values were considered out of stock (see methods).
A more liberal calculation which excludes missing
values from any calculation yields values of 94% stock in
2007 and 91% in 2008. This presents a noteworthy
improvement compared to previous years. There is still
room for improvement though, and ACCESS is continu-
ously working with the District Health Management
Teams to close the gap. The severe stock-outs of SP in
2006 during the months leading up to the introduction
of ALu showed the importance of having an alternative
source of anti-malarials in the community.
The high levels of stock of ALu in 2007 and 2008
coincided with the implementation of a “push” system
of delivery, which was implemented as a temporary
measure for the distribution of ALu to ensure its wide
availability. Although this system has led to high levels
of stock, it is argued not to be desirable in the long as it
leads to wastages when number of malaria patients is
lower than expected (e.g. as a result of malaria control
or the introduction of diagnostics). The National
Malaria Control Programme (NMCP) has been progres-
sively integrating the delivery of ALu into the national
drug delivery system and by the beginning of 2010 all
facilities should be placing orders for ALu along with
other items (Dr Mkude, NMCP, personal communica-
tion). The impact on stock levels need to be closely
monitored and evaluated.
Two other issues concerning the public health sector
emerged from the retail audits: 1) the low rate of pre-
scription of ALu; and 2) the non-adherence to user fee
exemptions. Although ALu was widely available in pub-
lic health facilities, it only accounted for 42% of anti-
malarials dispensed in health facilities. Similar findings
have been documented in Kenya [32,33]. In this study
amodiaquine was still largely dispensed (32%), although
the drug was no longer in stock (which does not
exclude it from being in the dispensing room). These
Table 5 Summary of changes in access to malaria treatment from the public health sector
Dimension Indicator Difference Change
Availability Facilities per 1000 population 0.13 in 2004 vs. 0.11 in 2008 (p = 0.712)
Proportion of months in stock of anti-malarial drugs Data not conclusive
Proportion of months in stock of the first-line anti-malarial 40% SP stock in 2006 vs. 81% ALu stock in 2008
(p < 0.001)
+
Affordability Median price of an adult anti-malarial dose SP TSH375 (in 2008 prices) in 2005 vs. SP TSH 300 in 2008
and ALu TSH300 in 2008
-
Accessibility Population within 5 km from a facility 73% in 2004 to 70% in 2008
(p < 0.001)
-
Median distance from a household to a facility 2.2 km in 2004 vs. 2.3 km in 2008
(p = 0.457)
Utilization Number of equivalent adult doses dispensed per day 79 in 2005 vs. 170 in 2008 +
Share of total sales through public health facilities 25% in 2005 vs. 30% in 2008
(p = 0.115)
Table 6 Summary of changes in access to malaria treatment from the private retail sector
Dimension Indicator Difference Change
Availability Shops per 1000 population 0.24 in 2004 vs. 0.39 in 2008 (p = 0.05) +
Proportion of licensed drug shops storing anti-malarials 86% in 2004 vs. 98% in 2008 (p = 0.019) but not
a constant trend over the years
Proportion of licensed drug shops storing the
first-line anti-malarial
86% selling SP in 2004 vs. 29% selling ALu in 2008
(p < 0.001)
+
Affordability Median price of adult anti-malarial dose SP TSH493 (in 2008 prices) in 2005 vs. SP TSH800
in 2008 and ALu TSH1500 in 2008
-
Accessibility Population within 5 km from a shop 72% in 2004 vs. 87% in 2008 (p < 0.001) +
Median distance from a household to a shop 2.2 km in 2004 vs. 1.2 km in 2008 (p < 0.001) +
Utilization Number of equivalent adult doses dispensed per day 154 in 2005 vs. 330 in 2008 +
Share of total sales through drug shops 49% in 2005 vs. 59% in 2008
(p = 0.036)
+
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Page 12 of 15findings differ from information extracted from user
surveys carried out a few months later (June to August)
according to which 63% of patients who were treated in
health facilities received ALu, 17% SP and 6% amodia-
quine. A deliberate attempt by health facility staff to
clear out any remaining stocks of amodiaquine in the
first half of the year could be an explanation for this.
This would be consistent with reasons documented in
Kenya for low ALu prescription. Indeed, factors deter-
mining low prescription of ALu by health workers were
not so much related to distrust in the drug, but more
with concerns over the cost of ALu, fears of future
stockouts and excess stocks of non-recommended anti-
malarial drugs [32]. The data presented here clearly sug-
gested a non-adherence to the user fee exemption given
that half of the health facilities reported selling ALu
packs for children under the age of eight. However, the
finding is not conclusive as only four out of 10 health
facilities provided pricing.
As far as the private sector is concerned both the
availability and accessibility of drug shops substantially
increased after the introduction of ADDOs. Interest-
ingly, there is evidence that ADDOs were opened in less
populated areas where there were previously no Part II
drug shops, suggesting that the programme may have
succeeded in encouraging shop owners to open ADDOs
in more remote areas.
General shops no longer play an important role in the
provision of anti-malarial treatment in the study area. A
study carried out in 2001 found that 27% of the general
shops selling drugs had anti-malarials in stock [3]. This
study found that the proportion of general shops selling
anti-malarial drugs decreased constantly between 2004
and 2008. There are a few possible explanations for
this. On one hand this may be due to tighter supervi-
sion by district authorities as a result of the ADDO
pilot in the area. However market mechanisms could
also be operating. General shops may have been com-
peted out of the market by the increase in the number
of licensed drug shops or the increase in prices of anti-
malarials.
T h eu s eo ft h ep r i v a t er e t a i lsector for malaria treat-
ment increased despite increases in prices and much
higher prices than in health facilities. Although prices of
anti-malarials alone do not s e r v ea sa ni n d i c a t i o no f
affordability, price changes over a relatively short period
of time provide a good indication of relative changes in
affordability. The price of the first-line treatment for
malaria increased by 84% and the price of SP by 51% in
drug shops whereas both decreased by 20% in health
facilities. Nevertheless, the share of doses sold in the
private retail sector increased from 49% to 59%. There
are many possible reasons behind this. Certainly
improvements in availability and accessibility of shops
must have contributed to their increased use. It might
also be the result of greater demand for ADDO pro-
ducts compared to the previous Part II drug shops.
Indeed, results from mystery shopper surveys conducted
in parallel to the shop censuses suggest a major
improvement in the quality of care in drug shops after
the introduction of ADDOs. The percentage of mystery
shoppers reporting with malaria symptoms increased
from just above 30% to nearly 80% between 2004 and
2008 (Dillip et al., unpublished data). Another possible
explanation could be the referral by health facility staff
to shops in which they have a financial stake in, given
that many ADDOs and Part II drug shops are owned
directly or indirectly by health facility workers, but data
from treatment-seeking surveys suggest that this was
not a major problem in the study area [20].
Despite the many improvements seen, the low avail-
ability of ALu in ADDOs is a major concern. Most
ADDO shop keepers reported selling ALu at its recom-
mended retail price of TSH 500 (approximately USD
0.40) for children doses and TSH 1500 (approximately
USD 1.30) for other doses. The results presented here
indicate that this level of subsidy did not result in wide-
spread availability of the drug. Discussions with ADDO
dispensers highlighted two main reasons for this: 1) the
drug can only be procured from one wholesaler in Mor-
ogoro, a city approximately 200 km from Ifakara; 2) the
drug is too expensive and leads to low profit margins.
A typical pre-packaged adult dose of SP was bought for
TSH 900 (USD 0.80) and sold for TSH1500 (USD 1.30).
Un-packaged SP was bought at the lower price of TSH
180 (USD 0.15) and sold for TSH 300 (USD 0.25). Con-
versely, a dose of ALu was bought for TSH 1150 (USD
1), which leaves a much lower profit margin than for
other drugs. The experience from two studies which
piloted the AMFm in Tanzania and Uganda where retail
mark-ups were higher found higher stocking rates
[34,35].
The findings presented here are highly relevant to
the imminent roll-out of the AMFm and confirm that
ensuring wide availability of ALu in the private retail
sector is paramount to its uptake. ADDOs are a suita-
ble distribution channel for ALu, since in the districts
where they exist, they are available, accessible and
highly utilized in both the district town and rural
areas. The data presented here suggest that the low
affordability of ALu in ADDOs ultimately restricted its
availability. Cheaper drugs, such as amodiaquine and
SP, were still the most dispensed drugs. AMFm plans
to subsidize ACT high in the distribution chain and to
facilitate their distribution at competitive prices along
the same channels as other anti-malarials could pre-
sent a viable solution to the problems encountered in
the study area.
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The public and private retail sector are important com-
plementary sources of malaria treatment in rural Tanza-
nia and efforts to improve access to prompt and
effective malaria treatment should take both sectors into
account. This duality of sources also offers a backup
solution when drugs are out of stock in the public heath
system. A high proportion of patients seek treatment for
malaria from shops rather than health facilities despite
higher prices, most likely because shops are more avail-
able and more accessible. The introduction of subsidized
ACT in the private retail sector was piloted in the study
area through the ADDO programme but did not lead to
high availability of the drug, probably because the final
price was not affordable. This resulted in a low uptake
of ACT despite its wide availability in public health
facilities. If a high quality of services is ensured in the
private sector the public health impact of ACT can be
maximized by making this class of drugs available at
affordable prices in the private sector.
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